CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference
CVRx, a commercial-stage medical device company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is set to present on Wednesday, August 14, 2024, at 12:30 PM Eastern Time. This presentation will be accessible to investors and interested parties through a live audio webcast on the investor relations page of CVRx's official website.
This event provides an opportunity for CVRx to showcase its progress and future plans to a wide audience of investors and industry professionals. The company's participation in such a prominent conference may indicate its commitment to transparency and engagement with the investment community.
CVRx, un'azienda medica in fase commerciale, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il team dirigenziale dell'azienda presenterà mercoledì 14 agosto 2024, alle 12:30 ora orientale. Questa presentazione sarà accessibile a investitori e parti interessate tramite un webcast audio in diretta nella pagina delle relazioni con gli investitori del sito ufficiale di CVRx.
Questo evento offre a CVRx l'opportunità di mostrare i progressi e i piani futuri a un ampio pubblico di investitori e professionisti del settore. La partecipazione dell'azienda a una conferenza così importante potrebbe indicare il suo impegno per la trasparenza e il coinvolgimento con la comunità degli investimenti.
CVRx, una empresa de dispositivos médicos en etapa comercial, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo directivo de la empresa está programado para presentar el miércoles 14 de agosto de 2024, a las 12:30 PM hora del Este. Esta presentación será accesible para inversores y partes interesadas a través de un webcast de audio en vivo en la página de relaciones con inversores del sitio web oficial de CVRx.
Este evento brinda a CVRx la oportunidad de mostrar sus avances y planes futuros a una amplia audiencia de inversores y profesionales de la industria. La participación de la empresa en una conferencia tan prominente puede indicar su compromiso con la transparencia y el compromiso con la comunidad de inversiones.
CVRx는 상업 단계의 의료 기기 회사로, Canaccord Genuity 제44회 연례 성장 회의에 참여한다고 발표했습니다. 회사의 경영진 팀은 2024년 8월 14일 수요일 동부 표준시 기준 오후 12시 30분에 발표할 예정입니다. 이 발표는 CVRx 공식 웹사이트의 투자자 관계 페이지를 통해 실시간 오디오 웹캐스트로 투자자 및 이해관계자들에게 제공됩니다.
이번 행사는 CVRx가 투자자 및 업계 전문가들에게 그들의 발전 상황과 미래 계획을 보여줄 수 있는 기회를 제공합니다. 이와 같이 저명한 회의에 참여하는 것은 투자 커뮤니티와의 투명성 및 참여에 대한 회사의 의지를 나타낼 수 있습니다.
CVRx, une entreprise de dispositifs médicaux en phase commerciale, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. L'équipe de direction de l'entreprise présentera mercredi 14 août 2024, à 12h30 heure de l'Est. Cette présentation sera accessible aux investisseurs et aux personnes intéressées via un webinaire audio en direct sur la page des relations avec les investisseurs du site web officiel de CVRx.
Cet événement offre à CVRx l'opportunité de présenter ses progrès et ses projets futurs à un large public d'investisseurs et de professionnels de l'industrie. La participation de l'entreprise à une conférence aussi prestigieuse pourrait indiquer son engagement envers la transparence et l'implication dans la communauté des investisseurs.
CVRx, ein Medizintechnikunternehmen in der Handelsphase, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Das Management-Team des Unternehmens wird am Mittwoch, den 14. August 2024, um 12:30 Uhr Eastern Time präsentieren. Diese Präsentation wird für Investoren und Interessierte über ein Live-Audio-Webcast auf der Investor-Relations-Seite der offiziellen Website von CVRx zugänglich sein.
Diese Veranstaltung bietet CVRx die Möglichkeit, seine Fortschritte und zukünftigen Pläne einem breiten Publikum von Investoren und Branchenfachleuten vorzustellen. Die Teilnahme des Unternehmens an einer so bedeutenden Konferenz könnte sein Engagement für Transparenz und den Dialog mit der Investmentgemeinschaft anzeigen.
- None.
- None.
MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 12:30 PM Eastern Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
FAQ
When is CVRx presenting at the Canaccord Genuity 44th Annual Growth Conference?
How can investors access CVRx's presentation at the Canaccord Genuity conference?
What is the stock symbol for CVRx?
What type of company is CVRx?
